Answers are grounded in this paper and cite their sources.
We used rats with streptozotocin (STZ)-induced diabetes to investigate the effects of Hachimi-jiogan on diabetic oxidative stress. Oral administration of Hachimi-jio-gan, at a dose of 50, 100 or 200 mg kg(-1) (body weight) daily, for 10 days to rats with STZ-induced diabetes resulted in significant dose-dependent decreases in serum levels of glucose and glycosylated protein, implying that Hachimi-jio-gan improves the abnormal glucose metabolism that leads to oxidative stress. Hachimi-jio-gan also showed a tendency to reduce the urine volume and significantly reduced the elevated urinary protein level. Moreover, rats with STZ-induced diabetes had high serum levels of superoxide and nitrite/nitrate. However, the administration of Hachimi-jio-gan dose-dependently reduced the overproduction of radicals associated with diabetes, suggesting the role of Hachimijio-gan as a radical scavenger that could protect against diabetic oxidative stress. Furthermore, thiobarbituric acid-reactive substance levels in serum and hepatic and renal mitochondria were dose-dependently lower in the Hachimi-jio-gan-treated groups than in the control diabetic group, which implies that Hachimi-jio-gan would alleviate the oxidative stress associated with diabetes through the inhibition of lipid peroxidation. These results indicate that Hachimi-jio-gan is a potential therapeutic agent that will reduce the damage caused by oxidative stress involved in diabetes.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: